Peoples Wellness & Longevity

Ozempic vs Wegovy vs Mounjaro:
Which GLP-1 Is Right for You?

An evidence-based comparison to help you make an informed decision about GLP-1 medications for weight loss and metabolic health

Choosing between Ozempic, Wegovy, and Mounjaro can feel overwhelming. While all three are GLP-1 receptor agonists approved for metabolic health, they have distinct differences in formulation, dosing, effectiveness, and FDA-approved indications.

This comprehensive comparison breaks down the key factors to help you and your healthcare provider determine which option aligns best with your health goals, lifestyle, and medical needs.

Side-by-Side Comparison

Ozempic
Wegovy
Mounjaro
Active Ingredient
Semaglutide
Semaglutide
Tirzepatide
FDA Approval
Type 2 Diabetes
Weight Management
Type 2 Diabetes
Max Dose
2 mg weekly
2.4 mg weekly
15 mg weekly
Avg. Weight Loss
10-15%
15-17%
18-22%
Mechanism
GLP-1 agonist
GLP-1 agonist
GLP-1 + GIP dual agonist
Common Side Effects
Nausea, diarrhea, constipation
Nausea, diarrhea, constipation
Nausea, diarrhea (often milder)
Monthly Cost
$900-$1,000
$1,300-$1,500
$1,000-$1,200
Best For
Type 2 diabetes + weight goals
Primary weight loss focus
Maximum weight loss results

Ozempic (Semaglutide)

FDA-Approved For: Type 2 diabetes management. Ozempic was the first semaglutide formulation approved by the FDA in 2017, specifically designed to improve blood sugar control in adults with type 2 diabetes. While not officially approved for weight loss, significant weight reduction has been consistently observed in clinical trials and real-world use.

Ozempic works by mimicking GLP-1, a naturally occurring hormone that regulates blood sugar and appetite. Administered as a once-weekly subcutaneous injection, it starts at 0.25 mg and can be titrated up to a maximum dose of 2 mg based on tolerance and therapeutic response. Most patients reach therapeutic benefit between 1-2 mg weekly.

Typical Patient Profile: Ozempic is ideal for individuals with type 2 diabetes who also want to lose weight. Clinical trials demonstrate an average weight loss of 10-15% of body weight over 68 weeks, along with significant improvements in HbA1c levels. It can be a strong fit for patients with dual metabolic concerns who want to address blood sugar and weight together.

What to Expect: Patients typically notice reduced appetite within the first few weeks. Nausea is the most common side effect, usually diminishing after the first month. Blood sugar improvements occur rapidly, while weight loss is gradual and sustained over 6-12 months. Long-term use is generally required to maintain results.

Wegovy (Semaglutide)

FDA-Approved For: Chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia. Approved in June 2021, Wegovy is the higher-dose formulation of semaglutide specifically designed for weight loss.

Wegovy uses the same active ingredient as Ozempic—semaglutide—but at a higher maximum dose of 2.4 mg weekly. This increased dosing was shown in the STEP clinical trial program to produce superior weight loss outcomes compared to lower doses. The medication is titrated gradually over 16-20 weeks to minimize gastrointestinal side effects.

Typical Patient Profile: Wegovy is best suited for individuals whose primary goal is significant weight loss, whether or not they have type 2 diabetes. In the landmark STEP 1 trial, participants lost an average of 15-17% of their body weight over 68 weeks. Wegovy is particularly effective for patients who have struggled with traditional diet and exercise approaches and need pharmacological support.

What to Expect: The higher dose means potentially greater weight loss, but also a higher incidence of gastrointestinal side effects during the titration phase. Most patients experience reduced hunger, smaller portion sizes, and decreased food cravings. Maximum weight loss typically occurs between 60-68 weeks, with maintenance dosing required to sustain results.

Mounjaro (Tirzepatide)

FDA-Approved For: Type 2 diabetes management (approved May 2022). Mounjaro represents a next-generation approach with its dual agonist mechanism. While currently approved only for diabetes, it's widely prescribed off-label for weight management due to impressive clinical trial results. A separate weight loss formulation (Zepbound) was approved in November 2023.

Unlike Ozempic and Wegovy, which target only GLP-1 receptors, Mounjaro activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual mechanism enhances insulin secretion, reduces appetite more effectively, and improves fat metabolism. Mounjaro is dosed weekly from 2.5 mg up to a maximum of 15 mg.

Typical Patient Profile: Mounjaro is ideal for individuals seeking maximum weight loss results or those who have had suboptimal responses to semaglutide-based medications. Clinical trials (SURMOUNT-1) demonstrated average weight loss of 18-22% at the highest doses—significantly more than any other GLP-1 medication. Patients often report fewer and milder gastrointestinal side effects compared to semaglutide.

What to Expect: Weight loss with Mounjaro is typically more pronounced and occurs more rapidly than with semaglutide. The dual mechanism appears to provide better metabolic improvements, including greater reductions in triglycerides and liver fat. Side effects are similar but often better tolerated. Because it's newer, long-term safety data is still accumulating. Supply has been more consistent than Wegovy, though it remains a meaningful monthly investment.

How to Decide: A Decision Framework

Choose Ozempic if:

  • You have type 2 diabetes and want better blood sugar control along with weight loss
  • You want to address type 2 diabetes and weight together
  • You want moderate weight loss (10-15%) with proven cardiovascular benefits
  • You prefer a medication with longer real-world track record (since 2017)

Choose Wegovy if:

  • Weight loss is your primary goal (not necessarily diabetes management)
  • You want the higher-dose semaglutide formulation specifically designed for weight management
  • You're looking for 15-17% body weight reduction with FDA backing for this indication
  • You want a medically supervised, results-driven weight loss plan

Choose Mounjaro if:

  • You want maximum weight loss results (18-22% body weight reduction)
  • You've tried semaglutide-based options with suboptimal results
  • You want a dual-action mechanism targeting both GLP-1 and GIP receptors
  • You experience significant GI side effects with semaglutide (often better tolerated)
  • You have type 2 diabetes and comprehensive metabolic concerns beyond weight

Important: The "best" option depends on your unique medical history, goals, and tolerance. A thorough consultation with a qualified provider is essential for personalized guidance.

Important Clinical Considerations

Time Commitment

All three medications require long-term commitment. Weight loss peaks around 60-68 weeks, and discontinuation typically leads to weight regain. Plan for ongoing treatment, regular monitoring, and lifestyle integration.

Cost

Brand-name GLP-1s run roughly $900-$1,500/month. We offer a medically supervised GLP-1 program with transparent cash-pay pricing, including compounded options and manufacturer savings programs where appropriate, to help manage cost.

Contraindications

Not suitable for patients with personal or family history of medullary thyroid cancer, multiple endocrine neoplasia syndrome type 2, pancreatitis, or severe GI disease. Pregnancy and breastfeeding are contraindications.

Monitoring Required

Regular follow-ups are essential to monitor weight, blood sugar, blood pressure, heart rate, and side effects. Lab work (lipids, kidney function, liver enzymes) should be checked periodically. Dose adjustments may be needed.

Frequently Asked Questions

Can I switch from Ozempic to Wegovy or Mounjaro?
Yes, switching between GLP-1 medications is common and generally safe under medical supervision. When switching from Ozempic to Wegovy, the transition is straightforward since both contain semaglutide—you simply adjust to the higher dose. Switching to Mounjaro requires starting at a low dose and titrating up, as the dual mechanism works differently. Your provider will create a transition plan based on your current dose, tolerance, and goals. Most patients experience minimal disruption when switching is done properly.
How long do side effects last?
Nausea, the most common side effect, typically peaks during the first 4-6 weeks and with each dose increase. Most patients find that symptoms significantly improve or resolve after 1-2 months at a stable dose. Strategies to minimize side effects include eating smaller meals, avoiding high-fat foods, staying well-hydrated, and taking the injection on a consistent day. If side effects are severe or persistent, dose adjustments or switching medications may be appropriate. Mounjaro users often report milder GI symptoms compared to semaglutide.
What happens if I stop taking the medication?
Clinical studies show that most patients regain weight after discontinuing GLP-1 medications, typically within 6-12 months. This occurs because the medications suppress appetite and regulate metabolism—effects that reverse when treatment stops. However, the weight regain trajectory varies. Some patients maintain a portion of their weight loss through sustained lifestyle changes. Others regain most or all of the weight. For lasting results, these medications should be viewed as long-term treatments, similar to blood pressure or cholesterol medications, combined with nutrition and exercise habits.
Do I still need to diet and exercise?
Yes. While GLP-1 medications significantly reduce appetite and facilitate weight loss, they work best as part of a comprehensive approach. Adequate protein intake is crucial to preserve muscle mass during weight loss. Regular resistance training helps maintain metabolic rate and prevent muscle loss. Cardiovascular exercise supports heart health and enhances results. Patients who combine medication with sustainable nutrition and activity habits achieve better outcomes, maintain more weight loss, and experience greater improvements in metabolic markers. Think of the medication as a powerful tool that makes healthy lifestyle changes easier to implement and sustain.
How do compounded versions compare to brand-name medications?
Compounded semaglutide and tirzepatide are available at lower cost through specialized pharmacies, but they are not FDA-approved and lack the same quality assurance, stability testing, and clinical trial backing as brand-name versions. Compounded medications may vary in potency, purity, and sterility between batches and pharmacies. Some patients achieve good results with compounded versions, while others notice differences in effectiveness or side effects. If cost is a barrier, compounded options may be worth discussing with your provider, but understand the tradeoffs. Always use a reputable, licensed compounding pharmacy that provides third-party testing certificates.

Ready to Discuss Your Options?

Schedule a consultation with our experienced providers to determine which GLP-1 medication is right for your unique health goals, medical history, and lifestyle.

Schedule Your Consultation

Or call us at (123) 456-7890

Medical Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual results vary based on medical history, adherence, lifestyle factors, and other variables. GLP-1 medications should only be prescribed and monitored by qualified healthcare providers after a comprehensive evaluation.

Weight loss percentages cited are based on clinical trial averages. Your results may differ. All medications carry risks and potential side effects. Discuss benefits, risks, and alternatives with your provider before starting any treatment.